Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy

Ajay K. Gopal, Brad S. Kahl, Christopher R. Flowers, Peter Martin, Stephen M. Ansell, Esteban Abella-Dominicis, Brian Koh, Wei Ye, Paul M. Barr, Gilles A. Salles, Jonathan W. Friedberg

Research output: Contribution to journalReview article

43 Scopus citations
Original languageEnglish (US)
Pages (from-to)3037-3039
Number of pages3
JournalBlood
Volume129
Issue number22
DOIs
StatePublished - Jun 1 2017

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Gopal, A. K., Kahl, B. S., Flowers, C. R., Martin, P., Ansell, S. M., Abella-Dominicis, E., Koh, B., Ye, W., Barr, P. M., Salles, G. A., & Friedberg, J. W. (2017). Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood, 129(22), 3037-3039. https://doi.org/10.1182/blood-2016-12-757740